Quantifying the contribution of lipoprotein(a) to all apoB containing particles

被引:3
作者
Chilazi, Michael
Zheng, Weili
Park, Jihwan
Marvel, Francoise A.
Khoury, Shireen
Jones, Steven R.
Martin, Seth S.
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Ciccarone Ctr Prevent Cardiovasc Dis,Div Cardiol, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA
关键词
Lipoprotein (a) [Lp(a); apolipoprotein B [apoB; apolipoprotein B100; apolipoprotein B48; particles; particle-based measurments; mass-based measurements; PLASMA; RISK; INTERVENTION; TRIGLYCERIDE; DOMAINS;
D O I
10.1016/j.jacl.2022.02.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Elevated lipoprotein (a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). As clinical LDL cholesterol [LDL-C] incorporates cholesterol from Lp(a) [Lp(a)-C], there is interest in quantifying the contribution of Lp(a)-C to LDL-C given implications for risk assessment, diagnosis, and treatment. Estimating Lp(a)-C is subject to inaccuracies; measuring Lp(a) particle number [Lp(a)-P] is more accurate. Objective: To capture how Lp(a) contributes to the concentration of atherogenic particles, we demonstrate a particle-based approach using readily available measures of Lp(a)-P and apolipoprotein B (apoB). Methods: Using the Very Large Database of Lipids (VLDbL), we compared Lp(a)-P (nmol/L) with all apoB containing particles ("apoB-P"). apoB-P was calculated by converting apoB mass to molar concentration using the preserved molecular weight of apoB100 (512 kg/mol). We calculated the percentage of Lp(a)-P relative to apoB-P by Lp(a)-P deciles and stratified by triglycerides, LDL-C, and non-HDL-C. Results: 158,260 patients from the VLDbL were included. The fraction Lp(a)-P/apoB-P increased with rising Lp(a)-P. Lp(a)-P comprised on average 3% of apoB containing particles among the study population and 15% at the highest Lp(a)-P decile. Lp(a)-P/apoB-P decreased at higher levels of triglycerides and LDL-C owing to larger contributions from VLDL and LDL. Conclusions: We demonstrate a particle-based approach to quantify the contribution of Lp(a) to all apoB-containing particles using validated and widely available clinical assays. This approach keeps in line with recommendations to move away from mass-based measurements of Lp(a) and prioritize more accurate particle-based measurements. Future research applying this method could define clinically meaningful thresholds and inform use in risk assessment and management.(c) 2022 National Lipid Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:220 / 226
页数:7
相关论文
共 23 条
[1]   Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes) [J].
Albers, John J. ;
Slee, April ;
O'Brien, Kevin D. ;
Robinson, Jennifer G. ;
Kashyap, Moti L. ;
Kwiterovich, Peter O., Jr. ;
Xu, Ping ;
Marcovina, Santica M. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (17) :1575-1579
[2]   APOLIPOPROTEIN(A) GENE ACCOUNTS FOR GREATER THAN 90-PERCENT OF THE VARIATION IN PLASMA LIPOPROTEIN(A) CONCENTRATIONS [J].
BOERWINKLE, E ;
LEFFERT, CC ;
LIN, JP ;
LACKNER, C ;
CHIESA, G ;
HOBBS, HH .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (01) :52-60
[3]   Comparability of Lipoprotein Particle Number Concentrations Across ES-DMA, NMR, LC-MS/MS, Immunonephelometry, and VAP: In Search of a Candidate Reference Measurement Procedure for apoB and non-HDL-P Standardization [J].
Delatour, Vincent ;
Clouet-Foraison, Noemie ;
Gaie-Levrel, Francois ;
Marcovina, Santica M. ;
Hoofnagle, Andrew N. ;
Kuklenyik, Zsuzsanna ;
Caulfield, Michael P. ;
Otvos, James D. ;
Krauss, Ronald M. ;
Kulkarni, Krishnaji R. ;
Contois, John H. ;
Remaley, Alan T. ;
Vesper, Hubert W. ;
Cobbaert, Christa M. ;
Gillery, Philippe .
CLINICAL CHEMISTRY, 2018, 64 (10) :1485-1495
[4]  
ELOVSON J, 1988, J LIPID RES, V29, P1461
[5]   Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease [J].
Ference, Brian A. ;
Kastelein, John J. P. ;
Ray, Kausik K. ;
Ginsberg, Henry N. ;
Chapman, John ;
Packard, Chris J. ;
Laufs, Ulrich ;
Oliver-Williams, Clare ;
Wood, Angela M. ;
Butterworth, Adam S. ;
Di Angelantonio, Emanuele ;
Danesh, John ;
Nicholls, Stephen J. ;
Bhatt, Deepak L. ;
Sabatine, Marc S. ;
Catapano, Alberico L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (04) :364-373
[6]   2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [J].
Grundy, Scott M. ;
Stone, Neil J. ;
Bailey, Alison L. ;
Beam, Craig ;
Birtcher, Kim K. ;
Blumenthal, Roger S. ;
Braun, Lynne T. ;
de Ferranti, Sarah ;
Faiella-Tommasino, Joseph ;
Forman, Daniel E. ;
Goldberg, Ronald ;
Heidenreich, Paul A. ;
Hlatky, Mark A. ;
Jones, Daniel W. ;
Lloyd-Jones, Donald ;
Lopez-Pajares, Nuria ;
Ndumele, Chiadi E. ;
Orringer, Carl E. ;
Peralta, Carmen A. ;
Saseen, Joseph J. ;
Smith, Sidney C., Jr. ;
Sperling, Laurence ;
Virani, Salim S. ;
Yeboah, Joseph .
CIRCULATION, 2019, 139 (25) :E1046-E1081
[7]   Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies [J].
Joshi, Parag H. ;
Khokhar, Arif A. ;
Massaro, Joseph M. ;
Lirette, Seth T. ;
Griswold, Michael E. ;
Martin, Seth S. ;
Blaha, Michael J. ;
Kulkarni, Krishnaji R. ;
Correa, Adolfo ;
D'Agostino, Ralph B. ;
Jones, Steven R. ;
Toth, Peter P. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (05)
[8]   Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) [J].
Khera, Amit V. ;
Everett, Brendan M. ;
Caulfield, Michael P. ;
Hantash, Feras M. ;
Wohlgemuth, Jay ;
Ridker, Paul M. ;
Mora, Samia .
CIRCULATION, 2014, 129 (06) :635-642
[9]   COMPLETE PROTEIN-SEQUENCE AND IDENTIFICATION OF STRUCTURAL DOMAINS OF HUMAN APOLIPOPROTEIN-B [J].
KNOTT, TJ ;
PEASE, RJ ;
POWELL, LM ;
WALLIS, SC ;
RALL, SC ;
INNERARITY, TL ;
BLACKHART, B ;
TAYLOR, WH ;
MARCEL, Y ;
MILNE, R ;
JOHNSON, D ;
FULLER, M ;
LUSIS, AJ ;
MCCARTHY, BJ ;
MAHLEY, RW ;
LEVYWILSON, B ;
SCOTT, J .
NATURE, 1986, 323 (6090) :734-738
[10]   Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases [J].
Kronenberg, Florian .
CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (01) :87-100